4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)benzoic acid | 1111660-19-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)benzoic acid
• 英文别名: 4-[1-(2-Trimethylsilylethoxymethyl)indazol-3-yl]benzoic acid
• CAS: 1111660-19-5
• 化学式: C₂₀H₂₄N₂O₃Si
• 分子量: 368.508
• InChiKey: YPWFYGVVMOPRPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.71
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)benzoic acid 在 四丁基氟化铵 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 tert-butyl 3-(4-(1H-indazol-3-yl)benzamido)propylcarbamate
  参考文献：
  名称：

  Design and Characterization of a Potent and Selective Dual ATP- and Substrate-Competitive Subnanomolar Bidentate c-Jun N-Terminal Kinase (JNK) Inhibitor

  摘要：

  c-Jun N-terminal kinases (JNKs) represent valuable targets in the development of new therapies. Present on the surface of JNK is a binding pocket for substrates and the scaffolding protein JIP1 in close proximity to the ATP binding pocket. We propose that bidentate compounds linking the binding energies of weakly interacting ATP and substrate mimetics could result in potent and selective JNK inhibitors. We describe here a bidentate molecule, 19, designed against JNK. 19 inhibits JNK kinase activity (IC50 = 18 nM; K-i = 1.5 nM) and JNK/substrate association in a displacement assay (IC50 = 46 nM; K-i = 2 nM). Our data demonstrate that 19 targets for the ATP and substrate-binding sites on JNK concurrently. Finally, compound 19 successfully inhibits JNK in a variety of cell-based experiments, as well as in vivo where it is shown to protect against Jo-2 induced liver damage and improve glucose tolerance in diabetic mice.

  DOI：

  10.1021/jm200479c
• 作为产物：
  描述：

  3-碘吲唑 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 水 、 sodium hydride 、 sodium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 35.5h， 生成 4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)benzoic acid
  参考文献：
  名称：

  Design and Characterization of a Potent and Selective Dual ATP- and Substrate-Competitive Subnanomolar Bidentate c-Jun N-Terminal Kinase (JNK) Inhibitor

  摘要：

  c-Jun N-terminal kinases (JNKs) represent valuable targets in the development of new therapies. Present on the surface of JNK is a binding pocket for substrates and the scaffolding protein JIP1 in close proximity to the ATP binding pocket. We propose that bidentate compounds linking the binding energies of weakly interacting ATP and substrate mimetics could result in potent and selective JNK inhibitors. We describe here a bidentate molecule, 19, designed against JNK. 19 inhibits JNK kinase activity (IC50 = 18 nM; K-i = 1.5 nM) and JNK/substrate association in a displacement assay (IC50 = 46 nM; K-i = 2 nM). Our data demonstrate that 19 targets for the ATP and substrate-binding sites on JNK concurrently. Finally, compound 19 successfully inhibits JNK in a variety of cell-based experiments, as well as in vivo where it is shown to protect against Jo-2 induced liver damage and improve glucose tolerance in diabetic mice.

  DOI：

  10.1021/jm200479c

文献信息

• [EN] BI-DENTATE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS BIDENTATE EN TANT QU'INHIBITEURS DE KINASE
  申请人：BURNHAM INST MEDICAL RESEARCH

  公开号：WO2009018490A1

  公开（公告）日：2009-02-05

  The present invention provides compound having the general structure A or pharmaceutically acceptable salts thereof: Het-L-P (A) wherein Het is an aromatic moiety comprising a heterocyclic structure mimicking ATP, P is a docking site derived peptide or a docking site peptide mimetic, and L is a linking moiety, wherein L links the ATP mimetic to the docking site peptide moiety. The compounds having the general structure A can serve as inhibitors of kinases, such as the kinases JNK, Erk and P38.

  本发明提供了具有一般结构A或其药学上可接受的盐的化合物：Het-L-P（A），其中Het是包含模拟ATP的杂环结构的芳香基团，P是源自肽的结合位点或模拟结合位点的肽，L是连接基团，其中L将ATP模拟物连接到结合位点肽基团。具有一般结构A的化合物可以作为激酶的抑制剂，例如激酶JNK、Erk和P38。